Wolverine Trading
IPXL

Wolverine Trading’s Impax Laboratories, Inc. IPXL Stock Holding History

Wolverine Trading’s Portfolio IPXL Stock Details IPXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-11,418
Closed -$151K – 5458
2016
Q4 		$151K Buy
+11,418
New +$195K ﹤0.01% 3912

Other funds holding IPXL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Wolverine Trading's IPXL Position: Q1 2017 in Review

Wolverine Trading sold out of Impax Laboratories, Inc. (IPXL) in Q1 2017, closing a stake of 11,418 shares — an estimated $151K sold.

Wolverine Trading first reported a position in IPXL in Q4 2016 and held it in 1 quarter. The position peaked at $151K in Q4 2016. 178 funds tracked by Wall St. Rank hold IPXL as of Q1 2017.

  • Wolverine Trading reported no remaining Impax Laboratories, Inc. position as of Q1 2017 after selling out during the quarter.
  • Wolverine Trading sold 11,418 Impax Laboratories, Inc. shares in Q1 2017, an estimated $151K.
  • Wolverine Trading first reported a position in Impax Laboratories, Inc. in Q4 2016 and held it in 1 quarter.
  • Wolverine Trading's Impax Laboratories, Inc. position peaked at $151K in Q4 2016.
  • 178 funds tracked by Wall St. Rank held Impax Laboratories, Inc. as of Q1 2017.

Based on Wolverine Trading's 13F filing for Q1 2017, filed 15 May 2017.